pancreaze
Generic: pancrelipase
pancreaze: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| VIVUS INC (VVUS) | Approved |
FDA Decisions
Approval1 INDICATIONS AND USAGE PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 )(VVUS)
Frequently asked questions
Who is developing pancreaze?
pancreaze is being developed by VIVUS INC.
What is pancreaze's latest FDA decision?
The most recent tracked FDA decision for pancreaze is Approval for 1 INDICATIONS AND USAGE PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. PANCREAZE ® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. ( 1 ), dated April 12, 2010.
Get deeper analysis on pancreaze
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis